Phase IIb Open-label Trial of SUBA-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Itraconazole (Primary)
- Indications Basal cell nevus syndrome
- Focus Registrational; Therapeutic Use
- Acronyms SCORING
- Sponsors HedgePath Pharmaceuticals
- 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History